Cargando…
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
A majority of patients with BRAF-mutated metastatic melanoma respond to therapy with BRAF inhibitors (BRAFi), but relapses are common owing to acquired resistance. To unravel BRAFi resistance mechanisms we have performed gene expression and mass spectrometry based proteome profiling of the sensitive...
Autores principales: | Azimi, Alireza, Tuominen, Rainer, Costa Svedman, Fernanda, Caramuta, Stefano, Pernemalm, Maria, Frostvik Stolt, Marianne, Kanter, Lena, Kharaziha, Pedram, Lehtiö, Janne, Hertzman Johansson, Carolina, Höiom, Veronica, Hansson, Johan, Egyhazi Brage, Suzanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596587/ https://www.ncbi.nlm.nih.gov/pubmed/29048432 http://dx.doi.org/10.1038/cddis.2017.406 |
Ejemplares similares
-
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
por: Azimi, A, et al.
Publicado: (2014) -
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
por: Falkenius, Johan, et al.
Publicado: (2017) -
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
por: Das, Ishani, et al.
Publicado: (2019) -
Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
por: Costa Svedman, Fernanda, et al.
Publicado: (2022) -
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
por: Vidarsdottir, Linda, et al.
Publicado: (2021)